DaVita Inc
NYSE:DVA

Watchlist Manager
DaVita Inc Logo
DaVita Inc
NYSE:DVA
Watchlist
Price: 165.51 USD 0.83% Market Closed
Market Cap: 13.6B USD
Have any thoughts about
DaVita Inc?
Write Note

DaVita Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

DaVita Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
DaVita Inc
NYSE:DVA
Other Long-Term Assets
$219m
CAGR 3-Years
29%
CAGR 5-Years
14%
CAGR 10-Years
13%
Chemed Corp
NYSE:CHE
Other Long-Term Assets
$55.7m
CAGR 3-Years
88%
CAGR 5-Years
44%
CAGR 10-Years
21%
Quest Diagnostics Inc
NYSE:DGX
Other Long-Term Assets
$272m
CAGR 3-Years
21%
CAGR 5-Years
12%
CAGR 10-Years
2%
CVS Health Corp
NYSE:CVS
Other Long-Term Assets
$8.1B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
18%
Cigna Corp
NYSE:CI
Other Long-Term Assets
$15.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
95%
Laboratory Corporation of America Holdings
NYSE:LH
Other Long-Term Assets
$612.6m
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
16%
No Stocks Found

DaVita Inc
Glance View

Market Cap
13.7B USD
Industry
Health Care

DaVita Inc. has emerged as a leading healthcare provider specializing in kidney care, operating over 2,800 outpatient dialysis centers across the United States and 10 additional countries. Founded in 1994, the company has made significant strides in enhancing the quality of life for individuals battling chronic kidney disease. With a mission deeply rooted in patient care, DaVita focuses on delivering comprehensive treatment and support, ensuring that patients receive not only dialysis services but also vital education and resources for managing their condition. This commitment to patient-centric care has positioned DaVita as a notable player in the burgeoning healthcare sector, making it an attractive investment opportunity for those interested in the resilience and growth potential within the industry. From an investor's perspective, DaVita represents a blend of stability and growth potential, driven by an aging population that increasingly requires kidney care services. The company benefits from a favorable reimbursement landscape and has implemented operational efficiencies that enhance profitability. In recent years, DaVita has also ventured into value-based care initiatives, which align incentives towards improved patient outcomes rather than volume. This strategic pivot not only secures a sustainable revenue model but also highlights the company’s adaptability in a rapidly changing healthcare environment. As such, DaVita stands out in the investment community, offering a chance to capitalize on a vital sector poised for expansion, all while contributing to the well-being of countless patients.

DVA Intrinsic Value
226.71 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is DaVita Inc's Other Long-Term Assets?
Other Long-Term Assets
219m USD

Based on the financial report for Sep 30, 2024, DaVita Inc's Other Long-Term Assets amounts to 219m USD.

What is DaVita Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
13%

Over the last year, the Other Long-Term Assets growth was -28%. The average annual Other Long-Term Assets growth rates for DaVita Inc have been 29% over the past three years , 14% over the past five years , and 13% over the past ten years .

Back to Top